tirofiban has been researched along with Syndrome in 49 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (12.24) | 18.2507 |
| 2000's | 41 (83.67) | 29.6817 |
| 2010's | 2 (4.08) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, SH; Li, W; Li, XS; Liang, CR; Liu, CC; Wang, H; Wang, YJ; Wu, Y; Xu, ZQ; Zhang, LL; Zhang, M | 1 |
| Acikel, S; Arslantas, U; Cimen, T; Dogan, M; Ertem, AG; Yeter, E | 1 |
| Banerjee, S; Blazing, MA; Braunwald, E; Brilakis, ES; Califf, RM; Cannon, CP; de Lemos, JA; Morrow, DA; Murphy, SA; Sabatine, MS; Wiviott, SD | 1 |
| Brener, SJ; Cannon, CP; Demopoulos, LA; DiBattiste, PM; Gibson, CM; Murphy, SA | 1 |
| Batchelor, WB; Califf, RM; Cantor, WJ; Davidian, M; DiBattiste, PM; Dillard, P; Gretler, D; Harrington, RA; Huang, Y; Larsen, RL; Mantell, RM; Ohman, EM; Sketch, MH; Tcheng, JE; Tolleson, TR; Zhang, D; Zidar, JP | 1 |
| Braunwald, E; Cannon, CP; Demopoulos, LA; DiBattiste, PM; Gibson, CM; McCabe, CH; Morrow, DA; Murphy, SA; Sabatine, MS | 1 |
| Böhm, M; Fries, R | 1 |
| Auer, J; Berent, R; Eber, B; Lassnig, E; Maurer, E; Weber, T | 1 |
| Alemao, E; Bakhai, A; Ben-Joseph, R; Collinson, JR; Flather, MD; Itzler, R; Normand, C; Stevens, W | 1 |
| Antman, EM; Bates, ER; Cohen, M; Every, NR; Ferguson, JJ; Harrington, RA; Pepine, CJ; Theroux, P | 1 |
| Huynh, T; Snapinn, S; Theroux, P; Wan, Y | 1 |
| Boden, WE; Cannon, CP; Januzzi, JL; Theroux, P | 1 |
| Antman, EM; Braunwald, E; Cannon, CP; Demopoulos, LA; DiBattiste, PM; Gibson, CM; Giugliano, RP; McCabe, CH; Morrow, DA; Murphy, SA; Rifai, N; Sabatine, MS; Wiviott, SD | 1 |
| DiBattiste, PM; Jang, IK; Januzzi, JL; Servoss, SJ; Snapinn, SM; Theroux, P; Wan, Y; Zhao, XQ | 1 |
| Hennebry, TA; Saucedo, JF | 1 |
| Barbieri, D; Ferrari, F; Ferrari, R; Guardigli, G; Parrinello, G; Percoco, G; Soukhomovskaia, O; Valgimigli, M | 1 |
| Hamm, CW; Heeschen, C; Lantelme, NH; Mitrovic, V; White, HD | 1 |
| DiBattiste, PM; Huynh, T; Pharand, C; Piazza, N; Snapinn, SM; Theroux, P; Wan, Y | 1 |
| Ardissino, D; Menozzi, A; Merlini, PA | 1 |
| Chang, ST; Cheng, NJ; Chung, CM; Yang, TY | 1 |
| Chun, KJ; Hong, TJ; Jeong, JH; Kim, JH; Park, YH; Shin, YW | 1 |
| Aroney, CN; Gunasekara, AP; Walters, DL | 1 |
| Badia, T; Bellandi, F; Dabizzi, RP; De Servi, S; Leoncini, M; Maioli, M; Politi, A; Toso, A | 1 |
| Bonizzoni, E; De Servi, S; Dellavalle, A; Leoncinie, M; Mariani, M; Poletti, F; Politi, A; Vandoni, P | 1 |
| Buckland, R; Judge, HM; Sastry, P; Siotia, A; Storey, RF | 1 |
| Alessi, MC; Barbou, F; Bonnet, JL; Cuisset, T; Frère, C; Hovasse, T; Quilici, J; Said, LN | 1 |
| Radke, PW; Schunkert, H | 1 |
| Münzel, TF; Post, F | 1 |
| Topaz, O | 1 |
| Adgey, AA | 1 |
| Ferguson, JJ; Lau, TK | 1 |
| Lindenfeld, J | 1 |
| Borzak, S; Cohen, M; Deckelbaum, LI; Diodati, JG; Harris, KE; Huynh, T; Laramée, P; Lo, MW; Sax, FL; Squire, IB; Théroux, P; Thornton, AR; Weber, S; White, HD | 1 |
| Galli, M; Maggioni, AP; Tavazzi, L; Vassanelli, C | 1 |
| Zidar, JP | 1 |
| Blankenship, JC; Frey, CM; Memon, MA; Menapace, FJ; Wood, GC | 1 |
| Jang, IK; Sabatine, MS | 1 |
| Holmes, DR | 1 |
| Agustí, A; Araujo, R | 1 |
| Alexander, J; Barr, E; Dupuis, J; Gervais, P; Grandmont, D; Huynh, T; Kouz, S; Laramée, P; Pesant, Y; Sax, FL; Théroux, P | 1 |
| Auer, J; Berent, R; Eber, B; Maurer, E; Mayr, H; Weber, T | 1 |
| Goldmann, BU; Hamm, CW | 1 |
| Popma, JJ; Suk, J | 1 |
| Galli, M; Vassanelli, C | 1 |
| Houghton, AR; Hudson, I; Patel, M | 1 |
| Chew, DP; Moliterno, DJ | 1 |
| Antman, EM; Braunwald, E; McCabe, CH; Morrow, DA; Snapinn, SM; Theroux, P | 1 |
| Bhatt, DL; Chew, DP | 1 |
19 review(s) available for tirofiban and Syndrome
| Article | Year |
|---|---|
Intravenous tirofiban therapy for patients with capsular warning syndrome.
Topics: Adult; Aged; Aged, 80 and over; Disability Evaluation; Female; Functional Status; Humans; Infusions, Intravenous; Ischemic Attack, Transient; Male; Middle Aged; Platelet Aggregation Inhibitors; Recovery of Function; Recurrence; Retrospective Studies; Syndrome; Time Factors; Tirofiban; Treatment Outcome | 2019 |
[Update cardiology 2001/2002-part II. From unstable coronary syndrome to terminal heart failure].
Topics: Abciximab; Acute Disease; Adrenergic beta-Antagonists; Angina, Unstable; Antibodies, Monoclonal; Anticholesteremic Agents; Arrhythmias, Cardiac; Aspirin; Atorvastatin; Clopidogrel; Defibrillators, Implantable; Double-Blind Method; Fibrinolytic Agents; Heart Failure; Heart Septal Defects, Atrial; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin Fab Fragments; Myocardial Infarction; Placebos; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Regeneration; Risk Factors; Syndrome; Ticlopidine; Time Factors; Tirofiban; Tyrosine | 2003 |
[Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
Topics: Abciximab; Administration, Oral; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Controlled Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Drug Therapy, Combination; Electrocardiography; Emergencies; Eptifibatide; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Factors; Stents; Syndrome; Thrombocytopenia; Thrombolytic Therapy; Time Factors; Tirofiban; Tyrosine | 2003 |
Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST-segment elevation acute coronary syndromes: risk stratification and therapeutic intervention.
Topics: Abciximab; Acute Disease; Aged; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Assessment; Syndrome; Tirofiban; Tyrosine | 2003 |
Use of the early invasive approach in the management of acute coronary syndromes.
Topics: Angina, Unstable; Cardiac Catheterization; Humans; Myocardial Infarction; Myocardial Revascularization; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Assessment; Syndrome; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
Tirofiban in acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Tirofiban; Tyrosine | 2005 |
[Antithrombotic treatment of acute coronary syndromes without ST-segment elevation].
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Clopidogrel; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Syndrome; Ticlopidine; Tirofiban; Tyrosine | 2006 |
[Pathogenesis and therapy of the acute coronary syndrome: differentiated advantage of glycoprotein IIb/IIIa receptor antagonists for high-risk patients].
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Coronary Thrombosis; Diabetes Complications; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Renal Insufficiency; Risk Factors; Syndrome; Ticlopidine; Tirofiban; Troponin; Tyrosine | 2006 |
An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Eptifibatide; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Tirofiban; Treatment Outcome; Tyrosine | 1998 |
New antiplatelet agents for acute coronary syndromes.
Topics: Abciximab; Acetates; Acute Disease; Antibodies, Monoclonal; Blood Platelets; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Tirofiban; Tyrosine | 1998 |
[The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
Topics: Acute Disease; Clinical Trials as Topic; Coronary Disease; Electrocardiography; Eptifibatide; Humans; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Syndrome; Tirofiban; Tyrosine | 2000 |
Glycoprotein IIb/IIIa receptor antagonists in acute coronary syndromes.
Topics: Abciximab; Acetates; Acute Disease; Antibodies, Monoclonal; Humans; Immunoglobulin Fab Fragments; Myocardial Ischemia; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Tirofiban; Tyrosine | 1999 |
Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis of major clinical trials.
Topics: Abciximab; Acetates; Acute Disease; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Drug Therapy, Combination; Eptifibatide; Heparin; Humans; Immunoglobulin Fab Fragments; Incidence; Infusions, Intravenous; Intracranial Hemorrhages; Odds Ratio; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Syndrome; Tirofiban; Tyrosine | 2000 |
The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
Topics: Abciximab; Acetates; Acute Disease; Administration, Oral; Alanine; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Benzamidines; Coronary Disease; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Oximes; Peptides; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic; Stents; Syndrome; Thrombocytopenia; Thrombolytic Therapy; Tirofiban; Tyrosine | 2000 |
Platelet glycoprotein receptor site blockade in coronary artery disease.
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Stents; Syndrome; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
[Acute coronary syndromes: an update. I. Pathogenesis and drug therapy].
Topics: Acute Disease; Administration, Oral; Adrenergic beta-Antagonists; Angina, Unstable; Anticoagulants; Aspirin; Calcium Channel Blockers; Clinical Trials as Topic; Clopidogrel; Electrocardiography; Fibrinolytic Agents; Humans; Multicenter Studies as Topic; Myocardial Infarction; Nitrates; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Syndrome; Terminology as Topic; Ticlopidine; Tirofiban; Tyrosine | 2001 |
Use of coronary revascularization in patients with unstable and non-ST-segment elevation acute myocardial infarction.
Topics: Angina, Unstable; Humans; Myocardial Infarction; Myocardial Revascularization; Randomized Controlled Trials as Topic; Risk Assessment; Syndrome; Thrombolytic Therapy; Tirofiban; Tyrosine | 2001 |
GP IIb/IIIa inhibitors in coronary artery disease management: what the latest trials tell us.
Topics: Abciximab; Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Atherectomy; Clinical Trials as Topic; Coronary Disease; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Placebos; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Syndrome; Time Factors; Tirofiban; Treatment Outcome; Troponin T; Tyrosine | 2001 |
Optimizing glycoprotein IIb/IIIa inhibition: lessons from recent randomized controlled trials.
Topics: Abciximab; Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Dose-Response Relationship, Drug; Drug Administration Schedule; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Syndrome; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
16 trial(s) available for tirofiban and Syndrome
| Article | Year |
|---|---|
Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).
Topics: Atorvastatin; Coronary Artery Bypass; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Care; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin; Syndrome; Thrombolytic Therapy; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2008 |
Efficacy and safety of multivessel percutaneous revascularization and tirofiban therapy in patients with acute coronary syndromes.
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Cohort Studies; Coronary Disease; Coronary Vessels; Female; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Severity of Illness Index; Survival Analysis; Syndrome; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, an
Topics: Abciximab; Acute Disease; Aged; Amino Acid Chloromethyl Ketones; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Citric Acid; Coronary Disease; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Kinetics; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Tirofiban; Tyrosine | 2002 |
Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservati
Topics: Acute Disease; Aged; Angina Pectoris; Biomarkers; C-Reactive Protein; Coronary Angiography; Coronary Artery Disease; Fees, Pharmaceutical; Female; Fibrinolytic Agents; Humans; Leukocyte Count; Male; Middle Aged; Multivariate Analysis; Severity of Illness Index; Smoking; Statistics as Topic; Stroke Volume; Survival Analysis; Syndrome; Tirofiban; Tyrosine | 2002 |
National economic impact of tirofiban for unstable angina and myocardial infarction without ST elevation; example from the United Kingdom.
Topics: Aged; Angina, Unstable; Anticoagulants; Cardiac Catheterization; Coronary Angiography; Coronary Disease; Electrocardiography; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Patient Admission; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Predictive Value of Tests; Prospective Studies; Risk Factors; Sensitivity and Specificity; Syndrome; Tirofiban; Treatment Outcome; Tyrosine; United Kingdom | 2003 |
Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Female; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).
Topics: Aged; Angina, Unstable; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Sex Factors; Syndrome; Tirofiban; Tyrosine | 2003 |
Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombo
Topics: Acute Disease; Aged; Angina, Unstable; Biomarkers; C-Reactive Protein; Combined Modality Therapy; Creatine Kinase; Creatine Kinase, MB Form; Female; Fibrinolytic Agents; Humans; Isoenzymes; Male; Middle Aged; Myocardial Infarction; Myocardium; Natriuretic Peptide, Brain; Sex Factors; Syndrome; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Troponin; Tyrosine | 2004 |
Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial.
Topics: Acute Disease; Angina Pectoris; Coronary Artery Bypass; Fibrinolytic Agents; Follow-Up Studies; Heparin; Humans; Myocardial Infarction; Myocardial Ischemia; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial.
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Coronary Stenosis; Creatine Kinase; Creatine Kinase, MB Form; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heparin; Humans; Intraoperative Complications; Isoenzymes; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation Inhibitors; Prevalence; Risk Factors; Syndrome; Tirofiban; Treatment Outcome; Troponin I; Tyrosine | 2004 |
N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes.
Topics: Acute Disease; Anticoagulants; Aspirin; Biomarkers; C-Reactive Protein; Drug Therapy, Combination; Follow-Up Studies; Heparin; Humans; Incidence; Myocardial Infarction; Myocardial Ischemia; Natriuretic Peptide, Brain; Nerve Tissue Proteins; Peptide Fragments; Predictive Value of Tests; Risk; Risk Assessment; Syndrome; Tirofiban; Troponin T; Tyrosine | 2004 |
Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstrea
Topics: Abciximab; Acute Disease; Aged; Angina, Unstable; Antibodies, Monoclonal; Clopidogrel; Creatine Kinase, MB Form; Electrocardiography; Female; Humans; Immunoglobulin Fab Fragments; Male; Myocardial Infarction; Necrosis; Prospective Studies; Syndrome; Ticlopidine; Time Factors; Tirofiban; Troponin I; Tyrosine | 2005 |
Utility of a whole blood single platelet counting assay to monitor the effects of tirofiban in patients with acute coronary syndromes scheduled for coronary intervention.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Drug Monitoring; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Prospective Studies; Syndrome; Tirofiban; Tyrosine | 2006 |
Combination therapy with tirofiban and enoxaparin in acute coronary syndromes.
Topics: Angina, Unstable; Coronary Angiography; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Injections, Intravenous; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Safety; Syndrome; Tirofiban; Treatment Outcome; Tyrosine | 1999 |
Upstream use of tirofiban in patients admitted for an acute coronary syndrome in hospitals with or without facilities for invasive management. PRISM-PLUS Investigators.
Topics: Acute Disease; Aged; Angina, Unstable; Anticoagulants; Canada; Cardiac Catheterization; Double-Blind Method; Female; Heparin; Hospitals; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Survival Analysis; Syndrome; Tirofiban; Treatment Outcome; Tyrosine | 2001 |
An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS.
Topics: Acute Disease; Aged; Angina, Unstable; Anticoagulants; Biomarkers; Coronary Disease; Creatine Kinase; Creatine Kinase, MB Form; Electrocardiography; Endpoint Determination; Follow-Up Studies; Heparin; Humans; Isoenzymes; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Predictive Value of Tests; Risk Assessment; Survival Analysis; Syndrome; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
14 other study(ies) available for tirofiban and Syndrome
| Article | Year |
|---|---|
From treatment to diagnosis of Kounis syndrome in the catherization laboratory: the resolution of vasospastic angina after intracoronary tirofiban and nitrate therapy.
Topics: Acute Coronary Syndrome; Cardiac Catheterization; Coronary Vasospasm; Coronary Vessels; Humans; Hypersensitivity; Male; Middle Aged; Nitrates; Syndrome; Tirofiban; Tyrosine | 2013 |
Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: insights from the PRISM-PLUS study.
Topics: Aged; Angina, Unstable; Anticoagulants; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Factors; Syndrome; Tirofiban; Tyrosine | 2005 |
Restoration of normal coronary flow with tirofiban by intracoronary administration for no-reflow phenomenon after stent deployment.
Topics: Aged; Coronary Circulation; Coronary Disease; Humans; Infusions, Intravenous; Male; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Syndrome; Tirofiban; Tyrosine | 2005 |
Safety of tirofiban therapy in korean patients with acute coronary syndrome.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Coronary Disease; Drug Evaluation; Female; Humans; Korea; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Syndrome; Tirofiban; Tyrosine | 2005 |
Comparison of abciximab with "high-dose" tirofiban in patients undergoing percutaneous coronary intervention.
Topics: Abciximab; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Australia; Diabetic Angiopathies; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Syndrome; Tirofiban; Troponin; Tyrosine | 2006 |
Use of glycoprotein IIb/IIIa inhibitors in invasively-treated patients with non-ST elevation acute coronary syndrome.
Topics: Abciximab; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Coronary Angiography; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Registries; Stents; Syndrome; Tirofiban; Tyrosine | 2006 |
[Platelet function after a high dose bolus of tirofiban immediately after coronary angioplasty].
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Syndrome; Time Factors; Tirofiban; Tyrosine | 2006 |
Ischemic coronary syndromes and SVG Interventions--do 2b/3a inhibitors miss the target?
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Coronary Disease; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Tirofiban; Tyrosine; Venous Thrombosis | 2007 |
Two new antiplatelet drugs for angioplasty and acute coronary syndromes.
Topics: Abciximab; Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Premedication; Syndrome; Tirofiban; Tyrosine | 1998 |
Safety and effectiveness of inhaled nitric oxide and tirofiban for acute coronary syndromes: a report from the cardiovascular and renal advisory panel of the food and drug administration.
Topics: Acute Disease; Administration, Inhalation; Coronary Disease; Humans; Nitric Oxide; Platelet Aggregation Inhibitors; Syndrome; Tirofiban; Tyrosine; United States; United States Food and Drug Administration; Vasodilator Agents | 1998 |
[Therapy of acute coronary syndrome with glycoprotein IIb/IIIa antagonists].
Topics: Abciximab; Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Atherectomy; Clinical Trials as Topic; Combined Modality Therapy; Coronary Disease; Eptifibatide; Fibrinolytic Agents; Heparin; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Syndrome; Tirofiban; Tyrosine; United States; United States Food and Drug Administration | 2000 |
[Risk stratification in acute coronary syndrome].
Topics: Abciximab; Acute Disease; Angina, Unstable; Antibodies, Monoclonal; Anticoagulants; Biomarkers; Clinical Trials as Topic; Coronary Disease; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Nadroparin; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Retrospective Studies; Risk Factors; Syndrome; Terminology as Topic; Tirofiban; Troponin I; Troponin T; Tyrosine | 2001 |
[Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban].
Topics: Coronary Disease; Humans; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Syndrome; Time Factors; Tirofiban; Tyrosine | 2001 |
Cost implications of routine tirofiban use in the management of acute coronary syndromes.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Coronary Disease; Eligibility Determination; Female; Health Care Costs; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Random Allocation; Syndrome; Tirofiban; Tyrosine | 2001 |